Yuko Mishima1,2, Yuji Mishima2, Masahiro Yokoyama1, Noriko Nishimura1, Yoshiharu Kusano1, Norihito Inoue1, Hideki Uryu1, Takanori Fukuta1, Yuko Shirouchi1, Kiyohiko Hatake3, Yasuhito Terui1,2 (1.Hematol Oncol, The Cancer Institute Hospital of JFCR, Tokyo, Japan, 2.Cancer chemotherapy center, Clinical Chemotherapy, Tokyo, Japan, 3.Hematology, International University of Health and Welfare School of Medicine)
Session information
Oral Session
Oral Session 2-9B Multiple Myeloma: Basic (2)
Sat. Oct 12, 2019 10:10 AM - 11:10 AM No.9 (Tokyo International Forum, 4F G402)
Chair: Masaki Ri (Division of Blood Transfusion and Cell Therapy, Nagoya City University Hospital)
Takashi Kanamori1,2, Masashi Sanada2, Masaki Ri1, Hiroo Ueno3, Dai Nishijima2, Takahiko Yasuda2, Sho Aoki1, Arisa Asano1, Takuto Tachita1, Shiori Kinoshita1, Tomoko Narita1, Asahi Ito1, Shigeru Kusumoto1, Atsushi Inagaki4, Yuta Masuda5, Nobuhiko Kobayashi6, Yusuke Shiozawa3,7, Kenichi Yoshida3, Masahiro Nakagawa3, Yasuhito Nanya3, Yuichi Shiraishi8, Kenichi Chiba9, Hiroko Tanaka9, Hirokazu Komatsu1, Satoru Miyano9, Hiroshi Handa5, Seishi Ogawa3,10,11, Shinsuke Iida1 (1.Department of Hematology and Oncology, Nagoya City University, Nagoya, Japan, 2.Clinical Research Center, Nagoya Medical Center, Nagoya, Japan, 3.Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 4.Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan, 5.Graduate School of Health Sciences, Gunma University, Maebashi, Japan, 6.Department of Medicine and Clinical Science, Gunma University, Maebashi, Japan, 7.Department of. Pediatrics, University of Tokyo, Tokyo, Japan, 8.Division of Cellular Signaling, National Cancer Center Research Institute, Japan, 9.Human Genome Center, Insti. of Med. Science, University of Tokyo, Tokyo, Japan, 10.WPI-ASHBi, Kyoto University, Kyoto, Japan, 11.Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden)
Shigeki Hirabayashi1,2, Hiroyuki Yamazaki2, Kotaro Shirakawa2, Akifumi Takaori2, Hideya Kawaji1,3, Yasuhiro Murakawa1,4 (1.RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan, 2.Department of Hematology and Oncology, Kyoto University, Kyoto, Japan, 3.RIKEN Preventive Medicine and Diagnosis Innovation Program, Kanagawa, Japan, 4.iFOM, The FIRC Institute of Molecular Oncology, Milan, Italy)
Shuku Sato, Wataru Kamata, Satomi Okada, Yotaro Tamai (Division of hematology, Shonan Kamakura General Hospital, Kamakura, Japan)
Ryosuke Kinoshita1, Mariko Ishibashi2, Mika Sunakawa1, Koichi Inokuchi1, Hiroshi Handa3, Makoto Sasaki4, Norio Komatsu4, Yoichi Imai5, Norina Tanaka6, Junji Tanaka6, Sakae Tanosaki7, Shigeki Ito8, Atsushi Isoda9, Morio Matsumoto9, Michiaki Koike10, Toshio Asayama1, Yasuko Kuribayashi1, Keiichi Moriya1, Hideto Tamura1 (1.Division of Hematology, Department of Medicine, Nippon Medical School, 2.Department of Microbiology and Immunology, Nippon Medical School, 3.Department of Hematology, Gunma University, 4.Division of Hematology, Juntendo University School of Medicine, 5.Department of Hematology and Oncology, IMSUT Hospital, 6.Department of Hematology, Tokyo Women's Medical University, 7.Department of Hematology, The Fraternity Memorial Hospital, 8.Department of Hematology and Oncology, Iwate Medical University, 9.Department of Hematology, National Hospital Organization Shibukawa Medical Center, 10.Department of Hematology, Juntendo University Shizuoka Hospital)
Kentaro Narita1, Takeshi Yoroidaka2, Hiroyuki Takamatsu2, Shinji Nakao2, Kosei Matsue1 (1.Division of Hematology/Oncology, Kameda Medical Center, Chiba, Japan, 2.Department of Hematology, Faculty of Medicine, Kanazawa University, Japan)